Prosecution Insights
Last updated: October 25, 2026
Application No. 18/983,718

Substituted Fused Bicyclic Compounds and Related Methods of Treatment

Non-Final OA §101
Filed
Dec 17, 2024
Priority
Jun 21, 2022 — provisional 63/354,025 +1 more
Examiner
VAJDA, KRISTIN ANN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Alkermes Inc.
OA Round
1 (Non-Final)
84%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1365 granted / 1628 resolved
+23.8% vs TC avg
Moderate +11% lift
Without
With
+11.1%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
52 currently pending
Career history
1665
Total Applications
across all art units

Statute-Specific Performance

§101
4.2%
-35.8% vs TC avg
§103
12.2%
-27.8% vs TC avg
§102
26.7%
-13.3% vs TC avg
§112
34.1%
-5.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1628 resolved cases

Office Action

§101
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-3, 14, 27, 36-39, 42-43, 45-46, 49, 61, 69, 71-72, 93, 109-110, 113-116, 134, 142, 160, 166, 178, 245-248, and 253-258 are pending in the instant application. Information Disclosure Statements The information disclosure statements filed on October 29, 2025 and May 22, 2026 have been considered and signed copies of form 1449 are enclosed herewith. Double Patenting A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957). A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101. Claims 1-3, 14, 27, 36-39, 42-43, 45-46, 49, 61, 69, 71-72, 93, 109-110, 113-116, 134, 142, 160, 166, 178, 245-248, and 253-258 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-3, 14, 27, 36-39, 42-43, 45-46, 49, 61, 69, 71-72, 93, 109-110, 113-116, 134, 142, 160, 166, 178, 245-248, and 253-258 of copending Application No. 18/983,714 (reference application). This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIN ANN VAJDA whose telephone number is (571)270-5232. The examiner can normally be reached Mon-Fri 6:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KRISTIN A VAJDA/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Dec 17, 2024
Application Filed
Sep 11, 2026
Non-Final Rejection mailed — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767653
PROCESS FOR PREPARATION OF SOTORASIB AND SOLID STATE FORM THEREOF
2y 11m to grant Granted Oct 20, 2026
Patent 12760003
MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE
2y 12m to grant Granted Oct 13, 2026
Patent 12759981
CHOLINATE OF 2-(1-CYCLOBUTYL-1H-PYRAZOL-4-YL)-5-[([{1-[2-FLUORO-4-(TRIFLUOROMETHYL)-PHENYL]CYCLOPROPYL}CARBONYL)AMINO]BENZOIC ACID
2y 9m to grant Granted Oct 13, 2026
Patent 12753423
BIOSYNTHESIS OF CHEMICALLY DIVERSIFIED NON-NATURAL TERPENE PRODUCTS
4y 5m to grant Granted Oct 06, 2026
Patent 12753147
NANOMATERIALS COMPRISING ACETALS
3y 3m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
84%
Grant Probability
95%
With Interview (+11.1%)
1y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1628 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month